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Study objectives: Community-acquired pneumonia is a frequent event in the course of
chronic obstructive pulmonary disease (COPD). The aim of the present study was to
provide information on clinical and microbiological characteristics and outcome of
community-acquired pneumonia in these patients, in a comparative study with the non-
COPD population.
Design: Prospective study of cases.
Setting: A university hospital in Lleida, Spain.
Patients: During a 6 year-period, we prospectively studied the clinical and radiological
manifestations, microbiological data and outcome of all patients with community-acquired
pneumonia. A comparative analysis of characteristics of pneumonia between 132 patients
with a definitive diagnosis of COPD and 575 patients who did not have this underlying
disease was performed.
Measurements and results: COPD was associated with an older and predominantly male
population. These patients frequently had concomitant comorbidities such as diabetes
mellitus or chronic heart failure. Clinical presentation was more severe, manifested by
septic shock, tachypnea, lower values of pH, pO2 and oxygen saturation, and greater
values of pCO2. Purulent expectoration was also more frequent in this subset of patients.
Admission was usually required for patients with COPD, and length of hospitalization was
significantly increased; however, difference in the mortality rate was not observed.
Although the spectrum of responsible microorganisms was very similar, the incidence of
Pseudomonas aeruginosa and other Gram-negative bacilli was increased in COPD,
particularly among patients with advanced situation and/or oral corticosteroid treatment.
Conclusions: Community-acquired pneumonia in patients with COPD was associated with
epidemiological and clinical particularities mainly related to the underlying disease butPublished by Elsevier Ltd.
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aeruginosa are potential pathogens that need to be considered.
& 2007 Published by Elsevier Ltd.Introduction
Chronic obstructive pulmonary disease (COPD) is a wide-
spread pathology that causes a high level of morbidity and
mortality.1 Community-acquired pneumonia constitutes one
of the most severe complications; epidemiological studies
show that COPD is the underlying disease most frequently
associated with pneumonia.2 Patients with COPD present
anatomopathological changes to the bronchial mucosa that
facilitate colonization of the lung by potentially pathologi-
cal micro organisms, which may lead to episodes of
pneumonia and a unique etiological and outcome spectrum
of conditions.3
In recent years several studies have been conducted with
patients affected by community-acquired pneumonia as a
result of a number of underlying illnesses, particularly
immunosuppressive diseases (neutropenia, HIV infection)4,5
or, less frequently, patients with diabetes mellitus.6 Never-
theless, the information available regarding patients
with COPD as underlying pathology is limited because of
the absence of a control group or the reduced sample. It
would be helpful to have broader studies that include
exhaustive etiological, clinical and outcome information, as
well as having a control group for comparing this data in
order to complete or corroborate the findings of previous
studies.
The present manuscript focuses on these points, attempt-
ing to more reliably understand the etiological spectrum of
the disease, as well as aspects related to the clinical
presentation and outcome of community-acquired pneumo-
nia in patients with COPD, simultaneously analyzing the
possible differences with respect to patients without this
underlying condition.Methods
Setting and study design
For a 6-year period (January 1998–December 2003), all
adult patients with community-acquired pneumonia diag-
nosed at the Emergency Room of the Arnau de
Vilanova University Hospital in Lleida (Catalonia, Spain)
were evaluated for inclusion in a prospective study of
epidemiological, clinical, microbiological, radiological and
outcome parameters. This study was evaluated and ap-
proved by the Scientific and Ethics Committees of the
institution.Clinical evaluation of patients
On enrollment, all patients underwent a complete physical
examination, had their clinical history recorded, and a chest
radiography, as well as basic chemistry and hematologytests. The presence of comorbid conditions was determined
by patient report and a review of medical records. The
validated Pneumonia Severity Index (PSI) prediction rule was
used to determine the severity of illness at presentation,
and patients were stratified into prognostic groups. Patient
complications and mortality during follow-up were also
recorded for a 30-day period after clinical resolution of the
pneumonia.
Definitions
Community-acquired pneumonia was defined as the pre-
sence of acute illness with features of lower respiratory
tract infection (two or more of the following signs and
symptoms: fever, new or increasing cough or sputum
production, dyspnea, chest pain or new focal signs on chest
examination) and the presence of a consolidation in the
chest radiography consistent with acute infection. In
absence of radiological findings, the clinical picture was
defined as COPD exacerbation. Patients with tuberculosis or
opportunistic infections were excluded from the study.
COPD was defined as a preventable and treatable disease
state characterized by airflow limitation that is not fully
reversible. The airflow limitation is usually progressive and
is associated with an abnormal inflammatory response of the
lungs to noxious particles or gases, primarily caused by
cigarette smoking that affects particularly the lungs but it
also produces significant systemic consequences. In addi-
tion, a spirometric test showing a post-bronchodilatador
FEV1/FVC p0.7 was required.7
Microbiological studies
Microbiological evaluation included testing of the following:
two blood samples for conventional aerobic and anaerobic
cultures; Gram stain and a culture of sputum, when
available; urine testing for Streptococcus pneumoniae or
Legionella pneumophila antigens with the rapid Binax Now
test (Leti Laboratories, Barcelona, Spain); Gram stain and
culture of pleural fluid, if a sufficient amount of pleural
effusion was radiologically detected; a sample of blood and
pleural fluid (if available) for S. pneumoniae DNA detection
by the polymerase chain reaction (PCR) method; and two
serum samples (at entry and between 4 and 6 weeks later)
for serological studies to detect antibodies against Myco-
plasma pneumoniae and L. pneumophila using the immuno-
fluorescence test, Coxiella burnetii and viruses (adenovirus,
influenza A, influenza B and parainfluenza) using the
complement fixation method, and Chlamydia psittaci and
Chlamydia pneumoniae using the microimmunofluorescence
test. The methodology for PCR testing in whole blood or
pleural fluid has been described in previous papers.8,9
According to the test results, etiologic diagnosis was
considered definitive when either a respiratory pathogen
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increase in serological titers was demonstrated, the
presence of the genome of S. pneumoniae was isolated
in blood or pleural fluid by PCR, or the antigen of
L. pneumophila or S. pneumoniae in urine was detected.
In contrast, etiologic diagnosis was considered presumptive
when a respiratory pathogen was isolated from a good-
quality sputum specimen or when high serological titers ( 1256
for immunofluorescence tests or 110 for complement fixation
tests) were found without seroconversion. The remaining
cases were defined as pneumonia of unknown etiology.
Statistical analysis
Univariate statistical analysis was performed for comparison
between subgroups of patients for qualitative variables,
using the chi-square or Fisher exact tests, and for
quantitative variables by using the t or Mann–Whitney tests.
The level of significance was established at po0.05.
Results
A total of 828 patients with community-acquired pneumonia
were enrolled in the study, of which 121 where excluded for
the following reasons: alternative diagnosis obtained during
the study in 103 cases, tuberculosis infection in 12 cases,
infection by opportunistic microorganisms in six cases (non-
tuberculous mycobacteria three, Aspergillus sp. two and
Nocardia asteroides one). A total of 707 patients were
analyzed, of which 367 (52%) presented one or more
underlying conditions, with COPD being the most common,
representing 132 (19%) patients. The other relatively common
comorbidities were diabetes mellitus in 122 (17%) cases,
cardiac heart failure in 66 (9%) and HIV infection in 51 (7%).
In these 132 patients with COPD, the disease was
characterized according to spirometric criteria as mild
(FEV1 between 60% and 80%) in 32% of patients, moderateTable 1 Baseline characteristics of patients distributed in su
disease (COPD)).a
Characteristics Patients with COPD
(n ¼ 132)
Age (yr) 70.3
Male sex 108 (82)
Alcohol abuse 18 (14)
Current smoking habit 32 (24)
Concomitant underlying diseases 129 (98)
HIV infection 1 (1)
Diabetes mellitus 32 (24)
Chronic heart failure 20 (15)
Chronic renal insufficiency 6 (5)
Chronic liver disease 5 (4)
Neoplasm 15 (11)
Cerebrovascular diseases 5 (4)
Prior antibiotic therapy 37 (28)
NS ¼ not significant.
aValues are given as the mean for continuous variables and No. (%(FEV1 between 40% and 59%) in 47%, and severe (FEV1 lower
than 40%) in 21%. Some 13% of patients received regular
treatment with oral corticosteroids and home oxygen
therapy in 8% of cases. The COPD diagnosis was established
during the hospital stay in 14 (10%) patients.
When comparing the epidemiological characteristics of
the patients by whether or not COPD was their underlying
pathology, as seen in Table 1, it is clear that the presence of
COPD defined a group of patients with higher mean age and
that were predominantly male, with a greater prevalence of
alcoholism, as well as being more frequently affected by
other concomitant pathologies such as diabetes mellitus or
cardiac insufficiency, although the prevalence of HIV was
lower.
With regard to the characteristics of the pneumonia
episodes (Table 2), both groups presented similar clinical
profiles. Nevertheless, while the existence of purulent
expectoration was most common among patients with COPD,
the appearance of fever was less frequent. Disease presenta-
tion in the form of septic shock was also statistically
associated with the presence of COPD as the underlying
condition. The greatest differences between the groups were
observed when comparing respiratory function parameters;
patients with COPD presented significantly lower values of
pH, pO2 and oxygen saturation, and significantly greater
values of pCO2. Mean respiratory frequency was also
significantly higher in patients with COPD. On the other
hand, the mean values for leukocytes and neutrophils were
lower in patients without COPD. Logically, these epidemio-
logical, clinical and analytical findings determined a worse
prognostic value for patients with the most severe forms of
COPD, if attention is paid to classification using the PSI index.
In relation to parameters associated with the outcome,
we did not found significant differences in mortality or need
for intensive care admission, although there was a tendency
to show less favorable results for patients with COPD.
Neither were there differences in the radiological extension

















) for categorical variables.
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Table 2 Comparison of clinical manifestations, radiological findings and laboratory results of patients distributed in
subgroups (with or without chronic obstructive pulmonary disease (COPD)).a





Acute onset 64 (48) 271 (47) NS
Typical clinical symptoms 66 (50) 267 (46) NS
Cough 106 (80) 423 (74) NS
Expectoration 89 (67) 278 (48) o0.001
Pleural chest pain 59 (45) 275 (48) NS
Signs of consolidation 101 (77) 432 (75) NS
Chills 40 (30) 221 (38) NS
Reduced level of consciousness 11 (8) 30 (5) NS
Multilobar infiltrate 24 (18) 98 (17) NS
Pleural effusion 32 (24) 122 (21) NS
Empyema 6 (5) 45 (8) NS
Septic shock 8 (6) 13 (2) 0.017
Systolic blood pressure (mmHg) 130 129 NS
Diastolic blood pressure (mmHg) 72 74 NS
Heart rate (beats/min) 100 97 NS
Respiratory rate (cycles/min) 31 26 o0.001
Temperature (1C) 37.7 38.1 0.001
ICU admission 18 (14) 48 (8) 0.068
Mortality 17 (13) 45 (8) 0.086
Length of hospitalization (days) 15 11 o0.001
Bacteremia 14 (11) 66 (11) NS
Leukocytes (mm3) 15926 13146 o0.001
Neutrophils (mm3) 13649 11210 o0.001
Hematocrit, % 40 38 NS
Plasma glucose (mg/dL) 159 139 0.006
Plasma urea (mg/dL) 56 48 0.017
Oxygen saturation (%) 89 95 0.002
pCO2 (mmHg) 38.2 37.4 o0.001
pH 7.44 7.45 0.011
NS ¼ not significant.
aValues are given as the mean for continuous variables and No. (%) for categorical variables.
R. Pifarre et al.2142empyema, or the detection of bacteremia. Only length of
hospitalization was significantly greater in COPD patients.
Finally, when we analyze the microbiological results
(Table 3) there are no clearly discordant results. Never-
theless, a detailed study suggests a greater incidence of
infection with Haemophilus influenzae and less detection of
the so-called atypical agents, although these differences
were not statistically significant. The most significant finding
is related to the isolation of Gram-negative bacilli, including
P. aeruginosa, as responsible agents for the pneumonia,
detected in 11% of patients with COPD in the study and only
in 3% of patients without COPD. Patients with COPD and
pneumonia due to P. aeruginosa were primarily patients with
moderate to severe disease 56
 




Our study included a broad group of patients with commu-
nity-acquired pneumonia, making it possible to determine
disease characteristics more exactly in the subgroup ofpatients with COPD as an underlying pathology. As other
authors have noted,10,11 community-acquired pneumonia
frequently affects these patients, who represented almost
20% of our total study population—the most prevalent group
within the study. It is not exceptional that the appearance of
a community-acquired pneumonia leads to the diagnosis of
this disease,2 which occurred in our case with 10% of the
patients enrolled. Previous studies have demonstrated that
a notable proportion of patients with COPD do not have an
established diagnosis.12
Logically, the epidemiological characteristics of patients
with COPD can be specific to this group and distinct from
that of other patients with community-acquired pneumo-
nia.13 It is not surprising to find that these patients had a
higher mean age and were predominantly male, factors
which are associated with a greater incidence of other
underlying diseases that are also associated with age, such
as diabetes mellitus or cardiac heart failure. Past history of
smoking, present in most of patients with COPD as a
fundamental etiological factor, may also contribute to this
greater prevalence of cardiac pathology. Finally, the
gasometric alterations and other parameters indicative of
ARTICLE IN PRESS
Table 3 Comparison of causative agents in patients
with and without chronic obstructive pulmonary disease
(COPD).a
Microorganisms Patients with
COPD (n ¼ 132)
Patients without
COPD (n ¼ 575)
Unknown
etiology
50 (38) 200 (35)
Streptococcus
pneumoniae
42 (32) 190 (33)
Other Gram-
positive cocci
5 (4) 25 (4)
Haemophilus
influenzae
4 (3) 11 (2)
Legionella
pneumophila
5 (4) 22 (4)
Pseudomonas
aeruginosa
6 (5) 5 (1)
Other Gram-
negative bacilli
8 (6) 16 (2)
Mycoplasma
pneumoniae
8 (6) 46 (8)
Chlamydia
pneumoniae




Coxiella burnetii 2 (2) 23 (4)
Anaerobes 0 2 (0.3)
Virus 5 (4) 17 (3)
aValues as given as No. (%).
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hypercapnia—are also coherent with a population of
patients with COPD.
As could be expected, the clinical manifestations of
community-acquired pneumonia in patients with COPD show
few differences with respect to patients without this
underlying pathology. The underlying chronic inflammatory
process in patients with COPD, secondary to the frequent
colonization of the lungs with potentially pathological
microorganisms and the hypertrophy of the mucosal glands
of the bronchial epithelium as an anatomopathological
substrate, explain the more frequent appearance of
purulent expectoration.3 On the other hand, the lack of
fever in a greater percentage of patients could be attributed
to several causes. For example, it is a well-known fact that
in patients with community-acquired pneumonia, greater
age is associated with a decreased incidence of clinical
symptoms.14 Also, treatment with corticosteroids in an
important percentage of patients may contribute to the
apyrexia seen in some of them. It is unknown if these
factors may mean greater risk of delayed pneumonia
diagnosis for patients with COPD and explain the finding,
in our study, of clinical presentation in the form of septic
shock. Differences in leukocyte and neutrophil counts and
glucose level, although statistically significant, do not
provide useful information for the management of these
patients.Several recently published studies on COPD patients found
that community-acquired pneumonia was associated with
admission to the intensive care unit and higher mortal-
ity.15,16 Outcome of our patients also tended to be poor,
although many of differences were not significant. Thus, a
greater percentage of these patients needed to be admitted
to intensive care units and were dead, but only the length of
hospitalization was significantly increased. Neither was a
study of prognostic factors, conducted by Fine et al.17 in an
extensive number of patients, able to associate this
diagnosis with an increase in mortality. Nevertheless, it is
very clear that other parameters associated with COPD
(hypoxemia) or the epidemiological characteristics
of these patients (age, cardiac insufficiency) were asso-
ciated, in that study, with an increase in mortality. More
recently other authors have observed a correlation between
pCO2 values and a poor prognosis of community-acquired
pneumonia.18
The microbiological results probably constitute one of the
most significant findings in the study. Community-acquired
pneumonia caused by Gram-negative bacilli and P. aerugi-
nosa is an uncommon diagnosis that represented 3% of the
study population but 11% of the study patients with COPD.
The association of P. aeruginosa with the existence of
chronic respiratory pathology has been suggested in other
studies.10,11 Certainly immunosuppression, which can be
caused by habitual treatment with oral corticosteroids, nor
alterations of the parenchyma or the pulmonary airways,
represented fundamentally by the patient with bronchiec-
tasis, has been considered in national and international
guidelines as pertaining to groups at risk for contracting
pneumonia due to P. aeruginosa.19,20 According to our
results, patients with moderate to severe COPD, particularly
if they receive routine oral corticosteroid treatment, can be
considered to be included in one of these risk groups, with
the therapeutic consequences implied. Without doubt
community-acquired pneumonia due to Gram-negative
bacilli supposes a very severe illness associated with
increased mortality if early and effective treatment is not
established.
Previous studies dedicating to determining the specific
characteristics of community-acquired pneumonia in
patients with COPD are scarce. Only the studies by Torres
et al., published in 1996, and Ruiz de Ocan˜a et al., published
in 2003, deserve to be categorized as such.13,21 The findings
of the first study dealt with describing the microorganisms
responsible for pneumonia, which are apparently no
different than those that can be found in the general
population, producing a global mortality of 8%. The absence
of a control group of patients without this underlying
pathology makes evaluating the study results difficult. The
second study, in a smaller number of patients, attributes
greater severity to pneumonia in patients with COPD.
Finally, a study published by Lieberman et al. can be
characterized as much more modest, and is based on a very
small number of patients with COPD.22
In summary, our study provides additional information
about characteristics of community-acquired pneumonia in
patients with COPD, showing some clinical and outcome
particularities, and especially useful microbiological data
to guide the development of more adequate empirical
treatments.
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